Login to Your Account



IPF 'Graveyard' Gets 1 More; Gilead Drops Work on Letairis

By Jennifer Boggs


Monday, December 27, 2010
With Gilead Sciences Inc. halting work on Letairis (ambrisentan) in idiopathic pulmonary fibrosis (IPF) after a peek at Phase III data showed a lack of efficacy, InterMune Inc.'s pirfenidone remains the last late-stage player standing in IPF, a disease for which there are no approved drugs.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription